SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on www.business-standard.com June 21, 2019, titled "Sun Pharmaceutical gets four observations for Halol facility in Gujarat".The reply is awaited. Sun Pharmaceutical gets four observations for Halol facility in Gujarat
The regulator has also observed that lab control mechanisms were not documented Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia Company news: Sun Pharma announces Phase 2 results on psoriatic arthritis drug
Sun Pharmaceutical Industries on Friday announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor, ILUMYA, in patients with Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to Late-Breaking Phase 2 Data Showing Potential of ILUMYA for Psoriatic Arthritis, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Goldman downgrades Sun Pharma to sell'
The downgrade led to the stock ending down 3 per cent at Rs 389.80 on Tuesday. Sun Pharma falls 4% as Goldman Sachs downgrades stock
Shares of Sun Pharma traded 4.31 per cent down at Rs 384.55 on BSE. Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd